Back to top
more

Viatris (VTRS)

(Delayed Data from NSDQ)

$11.78 USD

11.78
5,088,157

+0.18 (1.55%)

Updated May 3, 2024 04:00 PM ET

After-Market: $11.80 +0.02 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Pfizer (PFE) Has Been Rallying This Year So Far

by Zacks Equity Research

Pfizer's (PFE) stock is up 5.8% this year, riding high on the success of its two-shot vaccine for COVID-19.

Viatris (VTRS) Beats on Q1 Earnings & Sales, Announces Dividend

by Zacks Equity Research

Viatris (VTRS) beats on Q1 earnings while sales surpass expectations. The company announces inaugural quarterly dividend.

Theravance (TBPH) Q1 Earnings Lag Estimates, Pipeline on Track

by Zacks Equity Research

Theravance's (TBPH) loss narrows in the first quarter of 2021 while revenues decline year over year.

Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q1 results.

Will Pfizer (PFE) Deliver a Beat This Earnings Season?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.

Tracey Ryniec headshot

Bear of the Day: Viatris (VTRS)

by Tracey Ryniec

This newly created healthcare leader disappoints on full-year guidance.

Theravance (TBPH) Q4 Earnings Top Estimates, Revenues In Line

by Zacks Equity Research

Theravance's (TBPH) loss narrows in the fourth quarter of 2020 while revenues meet the consensus estimate.

Viatris (VTRS) Declines on Lackluster Outlook, Announces Dividend

by Zacks Equity Research

Viatris (VTRS) declines after it announces outlook for 2021 and reaffirms strategic commitments.

Pfizer (PFE) Q4 Earnings Miss, Sales Beat, 2021 View Upbeat

by Zacks Equity Research

Pfizer (PFE) misses estimates for earnings while beating the same for sales. It provides an upbeat financial outlook for 2021.

Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the fourth quarter.

Is Mylan (VTRS) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Viatris (VTRS) to Cut Jobs as Part of Restructuring Initiative

by Zacks Equity Research

Viatris (VTRS) announces job cuts as part of additional details of its previously disclosed multi-year global restructuring initiative.

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

by Zacks Equity Research

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is difficult to gauge. However, stable pricing and improvement in demand in some countries in 2021 may bode well for RDY, BHC and VTRS.

Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed

by Zacks Equity Research

Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.